POWER3 MEDICAL PRODUCTS, INC.

Inactief instrument

Koers Power3 Medical Products, Inc.

Aandelen

US73936A1034

Biotechnologie & Medisch Onderzoek

slotkoers OTC Bulletin Board Andere beurzen
- ^USD	-

op al onze abonnementen*

Profiteer van dit aanbod

*Zie voorwaarden op de site

Nieuws in andere talen over Power3 Medical Products, Inc.

Power3 Medical Products, Inc. : Amarantus BioSciences Licenses Parkinson's Disease Diagnostic Biomarker Test from Power3 Medical Products	23-01-12
POWER 3 MED PROD : Power3 Medical to Publish Medical Breakthrough Documented During Clinical Trials of Power3 Medical's Flag Ship NuroPro® Diagnostic	20-05-10
POWER 3 MED PROD : Power3 Medical Announces Filing of Two Provisional Patent Applications with the USPTO	14-05-10
POWER 3 MED PROD : Power3 Presents State of the Company Report at the Economic Development Partners Luncheon	12-05-10
POWER 3 MED PROD : Power3's Dr. Ira L. Goldknopf Stated in an Interview That the Company Plans to Completely and Strategically Reposition Itself Through a Consolidation of Stem Cell, Diagnostic, and Therapeutic Companies and Intellectual Property	07-05-10

Managers en directeuren - Power3 Medical Products, Inc.

Managers	Titel	Leeftijd	Van
Helen R. Park CEO	Chief Executive Officer	87	07-09-08
Ira L. Goldknopf CHM	Chairman	76	01-05-04

Besturend	Titel	Leeftijd	Van
Ira L. Goldknopf CHM	Chairman	76	01-05-04
Helen R. Park CEO	Chief Executive Officer	87	07-09-08

Bedrijfsprofiel

Sector

Biotechnologie & Medisch Onderzoek

Meer informatie over het bedrijf

Sector Biotechnologie & Medisch Onderzoek - Andere

	Vaira. 1 jan.	Kapi.
MODERNA, INC.	+64,23%	55,07 mld.
IQVIA HOLDINGS INC.	-2,31%	41,79 mld.
LONZA GROUP AG	+44,36%	40,22 mld.
CELLTRION, INC.	-8,29%	28,17 mld.
ICON PUBLIC LIMITED COMPANY	+11,97%	26,28 mld.
ALNYLAM PHARMACEUTICALS, INC.	-21,16%	18,93 mld.
BIO-TECHNE CORPORATION	+7,54%	13,03 mld.
MEDPACE HOLDINGS, INC.	+27,17%	12,26 mld.
UNITED THERAPEUTICS CORPORATION	+25,72%	12,21 mld.

Biotechnologie & Medisch Onderzoek - Andere

-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.

PROFITEER NU